Start of Main Content

NRx (New Prescription)

What is an NRx?

An NRx (new prescription) refers to a new prescription for a medication, typically issued when a patient needs to continue their treatment. This differs from NBRx (new-to-brand prescription), which refers to a patient’s first prescription for a particular drug.

An NRx occurs when a patient’s initial prescription or refills are exhausted, and they need a new prescription to continue taking the medication. Patients can have multiple NRxs for a single drug over time, especially if the medication is part of a long-term treatment plan.

When patients return to their doctor for an NRx, the doctor may conduct new lab tests and assess the effectiveness of the medication. Based on these evaluations, the doctor might decide to continue with the current prescription, adjust the dosage, or switch to a different medication. This process is common for maintenance medications, such as those for diabetes or hypertension, ensuring regular monitoring and appropriate adjustments. 

How can Biopharma companies use NRx?

Biopharma companies can analyze NRx data to gain insights into their drug’s performance. Specifically:

  • Patient adherence: The average number of NRxs per patient can reveal how well patients adhere to the medication over time. A high number of NRxs may suggest good adherence, while a low number could indicate issues with the medication’s effectiveness or patient satisfaction.
  • Market performance: Trends in NRx data can help assess how well a drug performs in the market, especially for long-term maintenance therapies. If the average number of NRxs per patient is low, it might suggest that patients are discontinuing the medication or switching to alternatives.
  • Treatment efficacy: Regular monitoring through NRxs can provide insights into the drug’s long-term efficacy and tolerability, guiding future marketing strategies and product development.

Overall, understanding NRx trends helps biopharma companies optimize their marketing efforts and improve patient outcomes.